Evaluation of Transduction Properties of an Adenovirus Vector in Neonatal Mice

Figure 4

Immune responses in neonatal mice following systemic administration of an Ad vector. (a, b) Cytokine mRNA levels in the liver (a) and spleen (b) in neonatal and adult mice following systemic administration of an Ad vector. Mice were administered Ad-AHAL2 at a dose of 5.9 × 10¹¹ IFU/kg via retro-orbital sinus. Organs were collected 3 h after Ad vector administration to recover total RNA. All values were normalized to 1 by the data of PBS-administered adult mice. (c) Anti-Ad antibody titers in the neonatal and adult mice following Ad vector administration. Mice were administered Ad-AHAL2 as described in (a). Serum samples were collected at each time point. Anti-Ad antibody levels were determined by ELISA. The background level represents the data of the PBST containing 5% ImmunoBlock. (d) Anti-Ad antibody production following systemic administration of an Ad vector in mice of different ages. Mice of different ages were administered Ad-AHAL2 as described in (a). Serum samples were collected 21 days after injection. Anti-Ad antibody levels were determined by ELISA. (e) mSEAP production after the second injection of Ad-AHAmSEAP. Mice received Ad-AHAL2 at a dose of 5.9 × 10¹¹ IFU/kg via retro-orbital sinus. Ad-AHAmSEAP was administered 21 days after the first administration via tail vein at a dose of 5.9 × 10¹¹ IFU/kg. Serum mSEAP levels were measured 48 h after injection of Ad-AHAmSEAP. (f) Anti-Ad antibody production in neonatal mice following the second injection of an Ad vector. Serum samples were collected 21 days after the second injection. Anti-Ad antibody levels were determined by ELISA (DOL, day of life; Wks, weeks) ( animals per group for a, b, e, and f: animals per group for c: animals per group for d).

(a)

(b)

(c)

(d)

(e)

(f)